BioCentury
ARTICLE | Clinical News

Phase III enrollment complete for T-20 study

June 28, 2001 7:00 AM UTC

Trimeris (TRMS) and partner Roche (SWX:ROCZ) completed enrollment of 500 HIV patients in an open-label Phase III study of TRMS's T-20 HIV fusion inhibitor in North America and Brazil. The T20-301 stud...